Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025. Shareholders who have not voted have until 11:59pm ET on December 2, 2025 to submit votes.
The company reaffirmed regulatory progress after successfully submitting and receiving acceptance of an end-of-phase 1 meeting package to FDA on November 20, 2025, and said it remains on track to hold that meeting later in 2025 to discuss the clinical and approval pathway for Gemini for acute kidney injury (AKI). The company also referenced its November 6, 2025 financial report covering the three and nine months ended September 30, 2025, highlighting top-line PRIME clinical results and $9.6 million gross proceeds from a September 2025 warrant inducement.
Positive
- Quorum reached for December 3, 2025 special meeting
- Voting deadline: 11:59pm ET December 2, 2025
- FDA end-of-phase 1 package accepted on November 20, 2025
- Top-line PRIME clinical results reported in November 2025
- $9.6 million gross proceeds from September 2025 warrant inducement
Negative
- None.
News Market Reaction
On the day this news was published, REVB gained 0.15%, reflecting a mild positive market reaction. Argus tracked a trough of -9.2% from its starting point during tracking. This price movement added approximately $9K to the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, REVB showed a 2.83% gain while peers were mixed: QLGN up 7.72%, GLTO up 2.55%, SLXN up 1.58%, and ELAB and ENTO down 3.97% and 5.68%, respectively. Momentum scanner only flagged SLXN, suggesting REVB’s action was more stock-specific than broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Special meeting update | Neutral | +0.1% | Quorum reached for Dec 3, 2025 Special Meeting and voting reminder. |
| Nov 20 | Clinical/FDA update | Positive | -0.5% | FDA accepted end-of-phase 1 package for Gemini in AKI and PRIME data update. |
| Nov 06 | Quarterly earnings | Neutral | -2.9% | Q3 2025 financials, PRIME top-line results, cash and warrant inducement proceeds. |
| Oct 29 | Special meeting change | Neutral | -4.5% | Canceled adjourned Special Meeting and reset record date and meeting to Dec 3, 2025. |
| Oct 15 | Special meeting adjournment | Neutral | -2.2% | Adjourned Oct 15, 2025 Special Meeting to Oct 29, 2025 due to low participation. |
Recent price reactions to governance and clinical updates have been modest, with one positive clinical milestone drawing a slightly negative move while routine meeting logistics often coincided with small declines.
Over the last few months, Revelation Biosciences has focused on both clinical progress and capital/stockholder actions. An end-of-phase 1 FDA meeting package for Gemini in AKI was accepted on Nov 20, 2025, following Phase 1b PRIME safety and inflammatory-activity data and plans for a later-stage study in 2026. Financial results on Nov 6, 2025 highlighted PRIME top-line data, cash of $12.7 million, and warrant-related funding. Multiple special-meeting adjournments and rescheduling culminated in the Dec 3, 2025 Special Meeting, for which today’s article confirms quorum.
Regulatory & Risk Context
An amended Form S-3/A registered common shares underlying Class I warrants at a $2.20 exercise price. While the company is not selling shares under this prospectus, full cash exercise of all registered warrants could provide up to $28,743,000, representing potential future dilution alongside added funding capacity.
Market Pulse Summary
This announcement confirms that Revelation Biosciences reached quorum for its December 3, 2025 Special Meeting and reminds stockholders of the December 2 voting deadline. It ties into a broader series of governance steps supporting warrant-related approvals and follows FDA acceptance of an end-of-phase 1 package for Gemini in AKI and earlier PRIME data. Investors may watch upcoming regulatory milestones, any follow-on clinical plans, and future use of warrant-related capital.
Key Terms
clinical-stage medical
end-of-phase 1 meeting regulatory
FDA regulatory
acute kidney injury (AKI) medical
warrant inducement financial
AI-generated analysis. Not financial advice.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. As a reminder, if you have not yet voted you have until 11:59pm ET tomorrow, December 2, 2025, to vote.
"I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote," said James Rolke, Chief Executive Officer, Revelation.
On November 20, 2025, Revelation Biosciences announced its successful submission and acceptance of the end-of-phase 1 meeting package to FDA, and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).
On November 6, 2025, the company reported its financial results for the three and nine months ended September 30, 2025. Highlights include groundbreaking top-line results from the PRIME clinical study and gross proceeds of
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What does Revelation Biosciences reaching a quorum for the December 3, 2025 special meeting mean for REVB shareholders?
What is the voting deadline for Revelation Biosciences' (REVB) December 3, 2025 special meeting?
What regulatory milestone did Revelation Biosciences announce on November 20, 2025 for REVB?
How does the FDA end-of-phase 1 package acceptance affect Gemini's development for AKI (REVB)?
What financial highlights did Revelation Biosciences report for the periods ended September 30, 2025 (REVB)?
